Company leaders presented at Hub East and PAP conferences, introduced ShieldRx at Asembia, and appeared in key industry publications
WHIPPANY, N.J.–(BUSINESS WIRE)–ConnectiveRx, a leading provider of technology-enabled patient support and access solutions for specialty and branded medications, today recapped its thought leadership activity over the first half of 2026. The company’s pharma commercialization experts presented at industry events, shared perspectives on patient access and gross-to-net (GTN) strategies in key trade publications, and debuted ShieldRx, its new AI-driven pharmacy monitoring solution.
Conference Presentations and Industry Events
ConnectiveRx Debuts ShieldRx at Asembia 2026
At Asembia’s AXS26 Summit, ConnectiveRx formally introduced ShieldRx, its new AI-driven pharmacy monitoring and misuse-prevention solution. Embedded into existing pharmacy workflows, ShieldRx flags suspicious activity in real time so manufacturers can intervene before questionable claims are paid, ensuring copay funds are being used as the manufacturer intended.
Andy Buzbee at Hub and Specialty Pharmacy Models East
At Informa Connect’s Hub and Specialty Pharmacy Models East conference, ConnectiveRx SVP Andy Buzbee moderated the executive roundtable, “Navigating Industry Headwinds and Seizing Opportunities.” The discussion focused on how manufacturers and patient support organizations are dealing with consolidation, digital transformation, prior authorization complexity, and budget pressure, and how organizations can stay agile while keeping patient support the priority.
Kristine McGaughey at Hub and Specialty Pharmacy Models East
At the same conference, ConnectiveRx SVP of Implementation Kristine McGaughey moderated “Orchestrating the Pre-Launch Symphony – Building Cross-Functional Harmony.” The panelists discussed how manufacturers can align market access, patient services, field teams, analytics, and pricing stakeholders earlier in the launch process, and how integrating data into commercialization planning leads to stronger launch readiness. She has also published in Pharmaceutical Commerce magazine, providing guidance strategies for early hub launch planning, streamlined patient access, and measured AI adoption.
Joanne Biscardi at POC Now Summit 2026
At the annual POC Now Summit, ConnectiveRx SVP, Business Development & Sales Operations Joanne Biscardi moderated the panel, “Unlocking Point of Care’s True Impact with Patient-Centric Measurement.” The session focused on why traditional marketing mix models often undervalue POC’s impact and what better data inputs – from binary signals to patient-level exposure and HCP-level granularity – can mean for ROI accuracy and investment confidence.
Ticia Cawley at PAP Conference 2026
ConnectiveRx SVP, Patient Assistance Programs Ticia Cawley presented at Patient Assistance & Access Programs 2026 (PAP), joining “PAPs Under Pressure,” a session focused on aggressive PBM tactics like accumulators, maximizers, alternative funding programs, and GTN challenges that squeeze program budgets. The discussion also looked at how AI tools are creating new opportunities for efficiency and patient impact.
Media Interviews and Industry Commentary
Laura Blair on Hub Operations and Specialty Distribution
ConnectiveRx Chief Commercial Officer Laura Blair sat down with Pharmaceutical Commerce for a video interview series covering some of the hardest questions in patient support and specialty distribution, including where virtual and traditional pharmacy fulfillment each fall short, what drives hub inefficiency, and what AI can actually deliver on adherence.
Shivani Patel on Affordability Models and Automation for Speed-to-Therapy
ConnectiveRx VP of Product Management Shivani Patel participated in two video interviews with Pharmaceutical Executive focused on adapting affordability programs to a changing market, where AI speeds the path to therapy, and why human expertise still anchors hub services.
Cindy Baksh on Gross-to-Net Protection, Pharmacy Misuse, and Real-Time Intervention
In a video interview with Pharmaceutical Executive, ConnectiveRx Chief Product Officer Cindy Baksh discussed the growing problem of pharmacy-level copay fund misuse and the need for earlier-stage intervention. She highlighted how manufacturers need to catch questionable pharmacy activity when a claim is presented, prior to processing, and cut unexpected copay spend.
ConnectiveRx Continues Pharmaceutical Commerce Series
ConnectiveRx has continued its Pharmaceutical Commerce article series in 2026 following a 2025 launch by SVP Market Development Chris Dowd. Recent articles have looked at how manufacturers are approaching GTN pressure, patient access, and the growing need for earlier visibility into questionable copay activity.
About ConnectiveRx
ConnectiveRx is a leading technology-enabled pharmaceutical services company delivering patient and provider support, access, and adherence solutions for specialty and branded medications. In 2025, McKinsey & Company independently ranked ConnectiveRx #1 in copay services and highest in Net Promoter Score across the patient support services landscape. The company’s solutions include the industry’s leading patient engagement and access platform (hub services), patient and provider adherence messaging, patient affordability programs, and the iconic Physicians’ Desk Reference, now known as the Prescribers’ Digital Reference. To learn more, visit connectiverx.com or follow us on LinkedIn @ConnectiveRx.
Contacts
Jay Roberts, SRPR | [email protected]
